New drug tested for Tough-to-Treat lung cancer
NCT ID NCT07289048
Summary
This study is testing an experimental drug called IBI363 in people with advanced small cell lung cancer that has continued to grow despite previous treatments, including immunotherapy. The trial will enroll 35 patients to see how well the drug shrinks tumors and how safe it is. Participants will receive IBI363 until their cancer worsens, side effects become too severe, or they complete up to 24 months of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.